Skip to main content
. Author manuscript; available in PMC: 2014 Dec 21.
Published in final edited form as: J Immunol. 2009 Dec 2;184(1):359–368. doi: 10.4049/jimmunol.0902278

FIGURE 4.

FIGURE 4

HIV-1 primary isolates become sensitive to complement-mediated virolysis in the presence of rILYd4. HIV-1 primary isolates derived from six HIV-1–infected patients. PBMCs preincubated with rILYd4 (20 µg/ml), medium only, or anti-hCD59 monoclonal Ab (BRIC 229) were treated with heat-inactivated plasma from 5 HIV-1–positive individuals containing anti–HIV-1 envelope Abs (patients 1–5 shown in Table I) followed by exposure to 10% normal HS as a source of complement (heat-inactivated normal serum was used as a negative control). Each panel represents the sensitivity of HIV-1 virions derived from one patient to complement-mediated virolysis activated by the endogenous anti–HIV-1 Abs developed in five HIV-1–infected patients who were naive for antiretroviral therapy. Horizontal lines represent the mean. Statistical significance (p < 0.01 versus medium treatment group) is indicated by an asterisk.